NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 30.2% and is now trading at $15.73.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) announced its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The biotechnology company had revenue of $20 million for the quarter, compared to analysts' expectations of $19.31 million. The business's quarterly revenue was down 23.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) EPS.
View Vericel's earnings history.

Vericel issued an update on its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million.

5 Wall Street analysts have issued 1-year target prices for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Vericel's share price to reach $24.25 in the next year. This suggests a possible upside of 54.2% from the stock's current price.
View analysts' price targets for Vericel.

News coverage about VCEL stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vericel earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Vericel.

Some companies that are related to Vericel include Twist Bioscience (TWST), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), BAVARIAN NORDIC/S (BVNRY), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX) and Regenxbio (RGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by a number of retail and institutional investors. Top institutional investors include Fort Washington Investment Advisors Inc. OH (1.55%), GW&K Investment Management LLC (1.47%), New York State Common Retirement Fund (1.30%), Summit Creek Advisors LLC (1.05%), Mutual of America Capital Management LLC (0.87%) and Cadence Capital Management LLC (0.28%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Emerald Advisers LLC, GW&K Investment Management LLC, Falcon Point Capital LLC, Alps Advisors Inc., Fort Washington Investment Advisors Inc. OH, Mesirow Financial Investment Management Inc., and SG Americas Securities LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin.
View insider buying and selling activity for Vericel.

VCEL stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Summit Creek Advisors LLC, Cadence Capital Management LLC, WINTON GROUP Ltd, Conestoga Capital Advisors LLC, Rafferty Asset Management LLC, Trexquant Investment LP, and Mutual of America Capital Management LLC.
View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $15.73.

Vericel has a market capitalization of $709.58 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]